Despite the FDA mandating just a few weeks ago that all current CAR-T approved therapies must carry a box warning of […]

The interim results just posted of the DREAMM7 head-to-head trial show that the Blenrep combination in multiple myeloma offers great promise […]

As screening leads to early diagnosis, practice evolves to provide better patient outcomes.  This review article by Loria et al. […]

The 4th February of every year is always dedicated as World Cancer Day.  The primary goal of World Cancer Day […]

It is not often that clinical trials assess the treatment convenience of a therapy by testing the advantages of one […]

Results from the open-label, randomised AMBASSADOR trial reveal that disease-free survival (DFS) was doubled with adjuvant pembrolizumab therapy compared with […]

Antibody Drug Conjugates or ADCs are now so sufficiently optimised to work that their clinical performance is becoming something of an […]

For patients with locally advanced or metastatic urothelial (bladder) cancer, available treatment options after initial response to first-line therapy are […]

Immunotherapy CAR-T therapy has made a phenomenal difference to the treatment of various blood cancers since it was invented by Carl […]

Roche and its co-developer Halozyme reported that the European Commission has approved its marketing approval for the subcutaneous injectable form of […]